…ction of insulin ( e.g., syringes, alcohol pads, gauze), and are represented by RXCUIs [ 63 ] on the formulary file. In the HTI-1 Proposed Rule we requested comment on the appropriate scope for a “real-time prescription benefit” certification criterion, including whether a “real-…
… be a significant impact from a change in an RxNorm Concept Unique Identifiers (RXCUI) to RXC mapping, such as: (1) evidence of significant off-label prescribing (as was the case with hydroxychloroquine sulfate); [ 47 ] (2) abnormally large changes in clinical indications or prac…
… RxNorm to ATC and MeSH identifiers. For example, the RxNorm drug rosuvastatin (RxCUI: 301542) is linked to both the MeSH drug rosuvastatin (MeSH ID: C422923) and the 5th-level ATC drug rosuvastatin (ATC code: C10AA07). A given drug can be represented multiple times in ATC. Typic…
…nostic and billing codes, CPT (Current Procedural Terminology) procedure codes, RXCUI prescription codes, and encounters found in that period. Features are created as follows. We split the observation window of each paitent into four observation slices , specified relative to the…
…ful unit for reporting for drugs would be the RxNorm concept unique identifier (RxCUI). [ 170 ] The commenter suggested use of RxCUIs because it would minimize burden by reducing the list of entries (3,000 to 4,000 RxCUIs down from 100,000 active NDCs) and because existing prescr…
… drug qualifier, specifically via the use of RxNorm concept unique identifiers (RXCUIs), similar to how NDC identifiers are currently being used. The commenter stated that since most EHR technologies use proprietary commercial drug databases for their clinical terminology needs, …
… be a significant impact from a change in an RxNorm Concept Unique Identifiers (RXCUI) to RXC mapping, we will consider whether changes to the RXCUI to RXC mapping from the applicable data year crosswalk are appropriate. As background, RXC 07 (Anti Diabetic Agents, Except Insulin…
… be a significant impact from a change in an RxNorm Concept Unique Identifiers (RXCUI) to RXC mapping, we will consider whether changes to the RXCUI to RXC mapping from the applicable data year crosswalk are appropriate. As background, RXC 07 (Anti Diabetic Agents, Except Insulin…
…eneric equivalent, the Rx Norm Concept Unique Identifier ( printed page 17535) (RxCUI) associated with the brand and generic drug, if the brand drug was moved to a higher cost sharing tier or removed from the formulary, in a manner specified in the forthcoming PRA associated with…
… dosage, name of the generic equivalent, the Rx Norm Concept Unique Identifier (RxCUI) associated with the brand and generic drug, if the brand drug was moved to a higher cost sharing tier or removed from the formulary, in a manner specified in the forthcoming PRA associated with…
… MedID for drug classification instead of the RXNorm Concept Unique Identifier (RXCUI) system. The commenter noted MedID would improve stability, accessibility and predictability of the RXCs, as acquiring RXCUI mapping, keeping it up to-date, anticipating changes and ensuring dru…
… MedID for drug classification instead of the RXNorm Concept Unique Identifier (RXCUI) system. The commenter noted MedID would improve stability, accessibility and predictability of the RXCs, as acquiring RXCUI mapping, keeping it up to-date, anticipating changes and ensuring dru…
…l Coding System (HCPCS), are cross walked to RxNorm Concept Unique Identifiers (RXCUIs). [ 86 ] RXCUI mappings are always matched to the NDCs and HCPCS applicable to the particular EDGE data year as the NDC and HCPCS reflect the drugs that were available in the market during the …
… be a significant impact from a change in an RxNorm Concept Unique Identifiers (RXCUI) to RXC mapping, such as: (1) evidence of significant off-label prescribing (as was the case with hydroxychloroquine sulfate); [ 47 ] (2) abnormally large changes in clinical indications or prac…
…eneric equivalent, the Rx Norm Concept Unique Identifier ( printed page 17535) (RxCUI) associated with the brand and generic drug, if the brand drug was moved to a higher cost sharing tier or removed from the formulary, in a manner specified in the forthcoming PRA associated with…